SHANGHAI, March 27, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that an Investigational New Drug (IND) application for WuXi MedImmune’s novel anti-IL6 monoclonal antibody for rheumatoid arthritis has been accepted for review by the China Food and Drug Administration (CFDA).
In September 2012, MedImmune, the global biologics research and development arm of AstraZeneca, and WuXi AppTec formed the joint venture WuXi MedImmune Biopharmaceutical Co. Limited to develop and commercialize MEDI5117, a novel, investigational, long-acting monoclonal antibody for autoimmune and inflammatory diseases, the first such collaboration in China between a global company and a Chinese company to develop novel biologics. WuXi AppTec completed all CMC, nonclinical, and clinical sections of the dossier, and the wholly owned subsidiary of the joint venture filed an IND for it with the Jiangsu provincial FDA as a Class 1 therapeutic biologic in December 2014. WuXi AppTec’s biologics and pre-clinical facilities in Shanghai, Suzhou, and Wuxi passed the Jiangsu FDA’s onsite inspections in January 2015. The IND application has now been entered into the system of the CFDA for technical review. WuXi AppTec will continue to provide manufacturing for the program at its state-of-the-art biologics facilities, the first in China to meet cGMP standards of the United States, the European Union, and China, as well as provide local regulatory, pre-clinical, and clinical trial support.
“We are very pleased that our collaboration with MedImmune has advanced this important novel class 1 biologic on schedule,” said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. “WuXi’s capabilities in integrated biologics discovery, development, and manufacturing offer a global platform with the highest quality standards. This initiative showcases WuXi’s capabilities as a gateway for developing novel biologics in China.”
About WuXi PharmaTech
WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi PharmaTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information on WuXi’s biologics services, please visit: http://www.wuxiapptec.com/biologics.html.
For more information, please contact:
Ronald Aldridge
Director of Investor Relations
(201) 585-2048
ron_aldridge@wuxiapptec.com
Aaron Shi
Director of Corporate Communications
+86-21 5046-4362
aaron_shi@wuxiapptec.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/investigational-new-drug-application-for-wuxi-medimmunes-monoclonal-antibody-accepted-for-review-by-cfda-300056876.html
SOURCE WuXi PharmaTech (Cayman) Inc.
Help employers find you! Check out all the jobs and post your resume.
